1201 ORANGE STREET, WILMINGTON, DE
Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Reg. FD
Other Events
Announces Pricing of Public Offering of Common Stock
Announces Proposed Public Offering of Common Stock
News, Material Contracts
Annual Report to Security Holders
Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting.
Q1
Q3
Q2
Notice of Late Filing for Quarterly Report
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Offered under a Shelf Registration
RW
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notification Filed by a National Security Exchange
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement